Zhang Junyu, Chen Bocheng, Zhang Cangjian, Zhu Mengping, Fan Zhimin, Li Linjie, Wang Jinghan, Jin Jie
Lishui Municipal Central Hospital, Lishui, Zhejiang 323000, P.R. China.
Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, P.R. China.
iScience. 2024 Sep 10;27(10):110905. doi: 10.1016/j.isci.2024.110905. eCollection 2024 Oct 18.
In our investigation, we examined biochemical parameters and identified hydroxybutyrate dehydrogenase (HBDH) as a significant predictor for diffuse large B cell lymphoma (DLBCL) patients. A group of 100 patients was used to explore potential biomarkers related to progression-free survival (PFS). Subsequently, an independent cohort of 404 patients from a separate hospital was recruited to validate our findings. Our results revealed a strong association between elevated HBDH levels and poor PFS. Furthermore, although overexpression of LDHB, but not LDHA, was notably linked to poorer outcomes, HBDH expression emerged as a more robust predictor of clinical prognosis compared to LDH expression. Our investigations, which included metabolic and genetic pathway enrichment analyses, indicated that patients exhibiting heightened HBDH expression were characterized by distinct pathways related to energy metabolism and lymphoma progression. In conclusion, elevated HBDH levels were correlated with adverse survival and might serve as an independent parameter for evaluating patient outcomes.
在我们的研究中，我们检测了生化参数，并确定羟丁酸脱氢酶（HBDH）是弥漫性大B细胞淋巴瘤（DLBCL）患者的一个重要预测指标。我们使用一组100名患者来探索与无进展生存期（PFS）相关的潜在生物标志物。随后，我们从另一家医院招募了一个404名患者的独立队列来验证我们的发现。我们的结果显示，HBDH水平升高与不良的PFS之间存在密切关联。此外，虽然LDHB而非LDHA的过表达与较差的预后显著相关，但与乳酸脱氢酶（LDH）表达相比，HBDH表达是临床预后更强有力的预测指标。我们的研究包括代谢和遗传通路富集分析，结果表明，HBDH表达升高的患者具有与能量代谢和淋巴瘤进展相关的独特通路。总之，HBDH水平升高与不良生存相关，可能作为评估患者预后的一个独立参数。
